The company’s BG implant shunts aqueous to the tear film without risk of internal infection, and has developed a successful prototype with both bench and animal data.

The device is miniscule—about 1/100 the size of the most commonly implanted glaucoma device. The nanotechnology’s bands are also about 1/3 the size of the smallest bacteria, providing additional barriers to penetration. The central part of the device is hydrophilic hydrogel, which acts as a “shovel” of sorts to “scoop aqueous out to the surface of the eye.”

After 2 weeks, the device has consistent physiologic flow rate to maintain pressure below 12 mm Hg. There was also complete bacterial exclusion after 2 weeks. With the constant aqueous humor on the ocular surface, the implant may also help the 60% of glaucoma patients that develop dry eye, and may be a potential standalone dry eye treatment, Pulling said. Human trials are expected to begin in the next year.


Chris Pulling

Chris Pulling

Chris was most recently CEO of The Integra Group, a contract medical research organization he founded in 2002, until its recent successful sale to the world’s largest organization in the medical device sector.

View Full Profile


Get the Latest News, Podcasts and Videos.